Moore Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

Moore Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-40,000	Closed	-$1.03M	–	252
2017 Q3	$1.03M	Sell	40,000 -10,000	-20%	-$268K	0.02%	189
2017 Q2	$1.36M	Sell	50,000 -12,500	-20%	-$340K	0.04%	146
2017 Q1	$1.86M	Buy	+62,500	New	+$1.8M	0.05%	153

Other funds holding ACRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

SMV

Sofinnova Management VIII Menlo Park, California $183M AUM 4.18% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Moore Capital Management's ACRS Position: Q4 2017 in Review

Moore Capital Management sold out of Aclaris Therapeutics (ACRS) in Q4 2017, closing a stake of 40,000 shares — an estimated $1.03M sold.

Moore Capital Management first reported a position in ACRS in Q1 2017 and held it in 3 quarters. The position peaked at $1.86M in Q1 2017. 102 funds tracked by Wall St. Rank hold ACRS as of Q4 2017.

Moore Capital Management reported no remaining Aclaris Therapeutics position as of Q4 2017 after selling out during the quarter.
Moore Capital Management sold 40,000 Aclaris Therapeutics shares in Q4 2017, an estimated $1.03M.
Moore Capital Management first reported a position in Aclaris Therapeutics in Q1 2017 and held it in 3 quarters.
Moore Capital Management's Aclaris Therapeutics position peaked at $1.86M in Q1 2017.
102 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2017.

Based on Moore Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.